Drug Type Small molecule drug |
Synonyms TriRima, Tyrima, CX 157 + [3] |
Target |
Mechanism MAO-A inhibitors(Monoamine oxidase A inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC14H8F4O4S |
InChIKeyPDIMOTRDGUQMNY-UHFFFAOYSA-N |
CAS Registry205187-53-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Depressive Disorder, Treatment-Resistant | Phase 2 | US | 01 Nov 2010 | |
Depressive Disorder, Major | Phase 2 | US | 01 Sep 2008 | |
Anxiety Disorders | Phase 2 | - | - | |
Anxiety Disorders | Phase 2 | - | - | |
Depressive Disorder | Phase 2 | - | - |
Phase 2 | 285 | (Oral CX157 60 mg TID (Total Daily Dose of 180 mg)) | ehuntaxsxs(mhykhvshvk) = swubuvysvo jaantouvyj (wklecutakw, uhecnbyppk - grhfyfsbqt) View more | - | 27 Jun 2012 | ||
Placebo (Oral Placebo TID) | ehuntaxsxs(mhykhvshvk) = lohagcwvkd jaantouvyj (wklecutakw, qlhthqkbpp - mvvzdvybto) View more |